TOP - March 2020, Vol 13, No 2

Orlando, FL—A potent, oral small-molecule bromodomain and extraterminal domain (BET) inhibitor—CPI-0610—improves spleen volume and symptoms when added to the Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) in ruxolitinib-naïve patients with myelofibrosis. Read More ›

Patients with anemia and lower-risk myelodysplastic syndromes (MDS) in whom first-line erythropoiesis-stimulating agents (ESAs) are not effective generally become transfusion dependent. Read More ›

An increasing number of biosimilars have been approved in the United States, but many clinicians are still poorly informed about what constitutes a biosimilar, and what is involved in their unique pathway to approval, said Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of ­Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. Read More ›

Genetic cancer screening and testing are valuable tools that can be used for the early detection of familial/hereditary cancer syndromes. However, people living in rural, medically underserved areas may have difficulty accessing these potentially life-saving services. Read More ›

Leukemia is the most frequently diagnosed cancer in children and adolescents, representing approximately 1 of 3 cancers in these populations of patients. Read More ›

Barcelona, Spain—Treatment with ceritinib (Zykadia) led to excellent responses in patients with ALK-positive non–small-cell lung cancer (NSCLC) and brain metastases, according to results of the ASCEND-7 clinical trial, which enrolled only patients with ALK-positive NSCLC with newly diagnosed or progressive brain metastases. Read More ›